Speaker(s): 

Miranda Woosman PharmD, PGY1 resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher J DeFrancesco PharmD, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Recognize the clinical presentation and diagnostic features of beta blocker overdoses.

2. Identify pharmacokinetic differences between beta blockers. 

3. Evaluate the role of advanced therapies in severe beta blocker overdoses.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None